Company Directory / Research Services

Public · NASDAQ:CYTFor profitResearch ServicesLexington, MA, United States
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Cyteir was a clinical-stage oncology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Cyteir had CYT-0851 in development in combination with capecitabine and gemcitabine in a Phase 1/2 clinical study, including patients with advanced ovarian cancer.
Size
11-50 people: larger than 33% of companies with a size listed. 3 people list it on LinkedIn.
Age
14 years old.
Reach
Website ranked #6,153,477 in the world for traffic, about 1k visits a month. 5,460 followers on LinkedIn.
BiopharmaBiotechnologyPharmaceutical
Funding, as listed
$157M raised in total
What the source datasets report. We have not watched these rounds ourselves.
Everything the source datasets list about Cyteir Therapeutics, field by field. Contact details are held but never shown.
The company
Where
Size and reach
Funding, as listed
About this record
Research Services in United States.
Nurses InkPelham · 1 followers
Science 37Morrisville · 251-500 people · 27k followersNNorthwestern University Clinical &Translational Sciences Institute (NUCATS)Chicago · 11-50 people · 561 followers
UmedeorCambridge · 51-100 people · 7k followers
Strong StarSan Antonio · 51-100 people · 989 followers
20/20 Gene SystemsRockville · 11-50 people · 895 followersFrom the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 1,637,054 companies in United States and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.